文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Chalmers R A, Parker R, Simmonds H A, Snedden W, Watts R W

Biochem J. 1969 May;112(4):527-32. doi: 10.1042/bj1120527.

A patient with congenital deficiency of xanthine oxidase (EC 1.2.3.2) (xanthinuria) excreted the xanthine isomer 4,6-dihydroxypyrazolo[3,4-d]pyrimidine (oxipurinol) in his urine when the hypoxanthine isomer 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol) was given by mouth. 2. The identity of the oxipurinol that the patient excreted was established by mass spectrometry. 3. The mass spectra and infrared spectra of allopurinol, oxipurinol, hypoxanthine and xanthine are compared. 4. A mechanism for the fragmentation of these compounds that occurs during their mass-spectrometric investigation is proposed. 5. A possible metabolic pathway for the oxidation of allopurinol to oxipurinol in the absence of xanthine oxidase is discussed.

一名患有黄嘌呤氧化酶（EC 1.2.3.2）先天性缺陷（黄嘌呤尿症）的患者口服次黄嘌呤异构体4-羟基吡唑并[3,4-d]嘧啶（别嘌呤醇）后，其尿液中排出了黄嘌呤异构体4,6-二羟基吡唑并[3,4-d]嘧啶（氧嘌呤醇）。2. 通过质谱法确定了患者排出的氧嘌呤醇的身份。3. 比较了别嘌呤醇、氧嘌呤醇、次黄嘌呤和黄嘌呤的质谱和红外光谱。4. 提出了这些化合物在质谱研究过程中发生裂解的机制。5. 讨论了在缺乏黄嘌呤氧化酶的情况下别嘌呤醇氧化为氧嘌呤醇的可能代谢途径。

Chalmers R A, Parker R, Simmonds H A, Snedden W, Watts R W

Biochem J. 1969 May;112(4):527-32. doi: 10.1042/bj1120527.

A patient with congenital deficiency of xanthine oxidase (EC 1.2.3.2) (xanthinuria) excreted the xanthine isomer 4,6-dihydroxypyrazolo[3,4-d]pyrimidine (oxipurinol) in his urine when the hypoxanthine isomer 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol) was given by mouth. 2. The identity of the oxipurinol that the patient excreted was established by mass spectrometry. 3. The mass spectra and infrared spectra of allopurinol, oxipurinol, hypoxanthine and xanthine are compared. 4. A mechanism for the fragmentation of these compounds that occurs during their mass-spectrometric investigation is proposed. 5. A possible metabolic pathway for the oxidation of allopurinol to oxipurinol in the absence of xanthine oxidase is discussed.

一名患有黄嘌呤氧化酶（EC 1.2.3.2）先天性缺陷（黄嘌呤尿症）的患者口服次黄嘌呤异构体4-羟基吡唑并[3,4-d]嘧啶（别嘌呤醇）后，其尿液中排出了黄嘌呤异构体4,6-二羟基吡唑并[3,4-d]嘧啶（氧嘌呤醇）。2. 通过质谱法确定了患者排出的氧嘌呤醇的身份。3. 比较了别嘌呤醇、氧嘌呤醇、次黄嘌呤和黄嘌呤的质谱和红外光谱。4. 提出了这些化合物在质谱研究过程中发生裂解的机制。5. 讨论了在缺乏黄嘌呤氧化酶的情况下别嘌呤醇氧化为氧嘌呤醇的可能代谢途径。